SACHIN APTE portrait
  • Professor, Obstetrics And Gynecology

Languages

  • English, Fluent.

Publications

  • Wells AE, Mallen AM, Bui MM, Reed DR, Apte SM (date unknown). NTRK-1 fusion in endocervical fibroblastic malignant peripheral nerve sheath tumor marking eligibility for larotrectinib therapy: A case report. (pp. 141-144). Vol. 28. Accepted, .
  • Marchion DC, Xiong Y, Chon HS, Al Sawah E, Bou Zgheib N, Ramirez IJ, Abbasi F, Stickles XB, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Berglund AE, Lancaster JM (date unknown). Gene expression data reveal common pathways that characterize the unifocal nature of ovarian cancer. Vol. 209, 576.e1-576.e16. Accepted, .
  • Jim HS, Small B, Faul LA, Franzen J, Apte S, Jacobsen PB (date unknown). Fatigue, depression, sleep, and activity during chemotherapy: daily and intraday variation and relationships among symptom changes. Vol. 42, 321-33. Accepted, .
  • Greer BE, Koh WJ, Abu-Rustum NR, Apte SM, Campos SM, Chan J, Cho KR, Copeland L, Crispens MA, Dupont N, Eifel PJ, Gaffney DK, Huh WK, Kapp DS, Lurain JR 3rd, Martin L, Morgan MA, Morgan RJ Jr, Mutch D, Remmenga SW, Reynolds RK, Small W Jr, Teng N, Valea FA, National Comprehensive Cancer Networks. (date unknown). Cervical cancer. Vol. 8, 1388-416. Accepted, .
  • Kamath SG, Chen N, Xiong Y, Wenham R, Apte S, Humphrey M, Cragun J, Lancaster JM (date unknown). Gedunin, a novel natural substance, inhibits ovarian cancer cell proliferation. Vol. 19, 1564-9. Accepted, .
  • Hoffman MS, Xiong Y, Apte S, Roberts W, Wenham RM (date unknown). Twenty-year surgical trends in a gynecologic oncology fellowship training program: Implications for practice. Vol. 155, 359-364. Accepted, .
  • Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Cho KR, Chu C, Cohn D, Crispens MA, Dizon DS, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, George S, Han E, Higgins S, Huh WK, Lurain JR 3rd, Mariani A, Mutch D, Fader AN, Remmenga SW, Reynolds RK, Tillmanns T, Valea FA, Yashar CM, McMillian NR, Scavone JL, National Comprehensive Cancer Network. (date unknown). Uterine Sarcoma, Version 1.2016: Featured Updates to the NCCN Guidelines. Vol. 13, 1321-31. Accepted, .
  • Bansal N, Roberts WS, Apte SM, Lancaster JM, Wenham RM (date unknown). Electrothermal bipolar coagulation decreases the rate of red blood cell transfusions for pelvic exenterations. Vol. 100, 511-4. Accepted, .
  • Al Sawah E, Chen X, Marchion DC, Xiong Y, Ramirez IJ, Abbasi F, Bou Zgheib N, Chon HS, Wenham RM, Apte SM, Judson PL, Lancaster JM (date unknown). Perifosine, an AKT inhibitor, modulates ovarian cancer cell line sensitivity to cisplatin-induced growth arrest. Vol. 131, 207-12. Accepted, .
  • Marchion DC, Cottrill HM, Xiong Y, Chen N, Bicaku E, Fulp WJ, Bansal N, Chon HS, Stickles XB, Kamath SG, Hakam A, Li L, Su D, Moreno C, Judson PL, Berchuck A, Wenham RM, Apte SM, Gonzalez-Bosquet J, Bloom GC, Eschrich SA, Sebti S, Chen DT, Lancaster JM (date unknown). BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival. Vol. 17, 6356-66. Accepted, .
  • Vaccarello L, Apte SM, Diaz PT, Lewandowski GS, Copeland LJ (date unknown). Respiratory failure from metastatic choriocarcinoma: a survivor of mechanical ventilation. Vol. 67, 111-4. Accepted, .
  • Kuznicki M, Mallen A, McClung EC, Robertson SE, Todd S, Boulware D, Martin S, Quilitz R, Vargas RJ, Apte SM (date unknown). Dual antibiotic prevention bundle is associated with decreased surgical site infections. Vol. 30, 1411-1417. Accepted, .
  • Phillips KM, Faul LA, Small BJ, Jacobsen PB, Apte SM, Jim HS (date unknown). Comparing the retrospective reports of fatigue using the Fatigue Symptom Index with daily diary ratings in women receiving chemotherapy for gynecologic cancer. Vol. 46, 282-8. Accepted, .
  • Indermaur MD, Xiong Y, Kamath SG, Boren T, Hakam A, Wenham RM, Apte SM, Lancaster JM (date unknown). Genomic-directed targeted therapy increases endometrial cancer cell sensitivity to doxorubicin. Vol. 203, 158.e1-40. Accepted, .
  • Boren T, Xiong Y, Hakam A, Wenham R, Apte S, Wei Z, Kamath S, Chen DT, Dressman H, Lancaster JM (date unknown). MicroRNAs and their target messenger RNAs associated with endometrial carcinogenesis. Vol. 110, 206-15. Accepted, .
  • Bumgardner GL, Li J, Apte S, Heininger M, Frankel WL (date unknown). Effect of tumor necrosis factor alpha and intercellular adhesion molecule-1 expression on immunogenicity of murine liver cells in mice. Vol. 28, 466-74. Accepted, .
  • Bush SH, Apte SM (date unknown). Robotic-Assisted Surgery in Gynecological Oncology. Vol. 22, 307-13. Accepted, .
  • Wenham RM, Lapolla J, Lin HY, Apte SM, Lancaster JM, Judson PL, Gonzalez-Bosquet J, Herschberger A, Havrilesky LJ, Secord AA (date unknown). A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy. Vol. 130, 19-24. Accepted, .
  • Bou Zgheib N, Xiong Y, Marchion DC, Bicaku E, Chon HS, Stickles XB, Sawah EA, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Cubitt CL, Chen DT, Lancaster JM (date unknown). The O-glycan pathway is associated with in vitro sensitivity to gemcitabine and overall survival from ovarian cancer. Vol. 41, 179-88. Accepted, .
  • Judson PL, Al Sawah E, Marchion DC, Xiong Y, Bicaku E, Bou Zgheib N, Chon HS, Stickles XB, Hakam A, Wenham RM, Apte SM, Gonzalez-Bosquet J, Chen DT, Lancaster JM (date unknown). Characterizing the efficacy of fermented wheat germ extract against ovarian cancer and defining the genomic basis of its activity. Vol. 22, 960-7. Accepted, .
  • Hoffman MS, Ondrovic LE, Wenham RM, Apte SM, Shames ML, Zervos EE, Weinberg WS, Roberts WS (date unknown). Evaluation of the porcine model to teach various ancillary procedures to gynecologic oncology fellows. Vol. 201, 116.e1-3. Accepted, .
  • Tedjarati S, Baker CH, Apte S, Huang S, Wolf JK, Killion JJ, Fidler IJ (date unknown). Synergistic therapy of human ovarian carcinoma implanted orthotopically in nude mice by optimal biological dose of pegylated interferon alpha combined with paclitaxel. Vol. 8, 2413-22. Accepted, .
  • Vaccarello L, Apte SM, Copeland LJ, Boutselis JG, Rubin SC (date unknown). Endometrial carcinoma associated with pregnancy: A report of three cases and review of the literature. Vol. 74, 118-22. Accepted, .
  • Hammer DA, Apte SM (date unknown). Simulation of cell rolling and adhesion on surfaces in shear flow: general results and analysis of selectin-mediated neutrophil adhesion. Vol. 63, 35-57. Accepted, .
  • Chon HS, Kang S, Lee JK, Apte SM, Shahzad MM, Williams-Elson I, Wenham RM (date unknown). Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers. Vol. 17, 407. Accepted, .
  • Bicaku E, Xiong Y, Marchion DC, Chon HS, Stickles XB, Chen N, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Fulp W, Cubitt CL, Chen DT, Lancaster JM (date unknown). In vitro analysis of ovarian cancer response to cisplatin, carboplatin, and paclitaxel identifies common pathways that are also associated with overall patient survival. Vol. 106, 1967-75. Accepted, .
  • Teefey P, Bou Zgheib N, Apte SM, Gonzalez-Bosquet J, Judson PL, Roberts WS, Lancaster JM, Wenham RM (date unknown). Factors associated with improved toxicity and tolerability of intraperitoneal chemotherapy in advanced-stage epithelial ovarian cancers. Vol. 208, 501.e1-7. Accepted, .
  • Marchion DC, Bicaku E, Xiong Y, Bou Zgheib N, Al Sawah E, Stickles XB, Judson PL, Lopez AS, Cubitt CL, Gonzalez-Bosquet J, Wenham RM, Apte SM, Berglund A, Lancaster JM (date unknown). A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Vol. 29, 2011-8. Accepted, .
  • Schmeler KM, Vadhan-Raj S, Ramirez PT, Apte SM, Cohen L, Bassett RL, Iyer RB, Wolf JK, Levenback CL, Gershenson DM, Freedman RS (date unknown). A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer. Vol. 113, 210-5. Accepted, .
  • Boren T, Xiong Y, Hakam A, Wenham R, Apte S, Chan G, Kamath SG, Chen DT, Dressman H, Lancaster JM (date unknown). MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Vol. 113, 249-55. Accepted, .
  • Apte SM, Vadhan-Raj S, Cohen L, Bassett RL, Gordon IO, Levenback CF, Ramirez PT, Gallardo ST, Patenia RS, Garcia ME, Iyer RB, Freedman RS (date unknown). Cytokines, GM-CSF and IFNgamma administered by priming and post-chemotherapy cycling in recurrent ovarian cancer patients receiving carboplatin. Vol. 4, 16. Accepted, .
  • Boac BM, Xiong Y, Apte SM, Wenham RM, Shahzad MM, Munroe DG, Lancaster JM, Chon HS (date unknown). Adherence to practice guidelines is associated with reduced referral times for patients with ovarian cancer. Vol. 218, 436.e1-436.e7. Accepted, .
  • Apte SM (date unknown). An oncologist's perspective: preparation for new payment models in cancer care. Vol. 23, SP169-SP172. Accepted, .
  • Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Cho KR, Chu C, Cohn D, Crispens MA, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, Han E, Huh WK, Lurain JR 3rd, Mutch D, Fader AN, Remmenga SW, Reynolds RK, Teng N, Tillmanns T, Valea FA, Yashar CM, McMillian NR, Scavone JL (date unknown). Cervical Cancer, Version 2.2015. Vol. 13, 395-404. Accepted, .
  • Stickles XB, Marchion DC, Bicaku E, Al Sawah E, Abbasi F, Xiong Y, Bou Zgheib N, Boac BM, Orr BC, Judson PL, Berry A, Hakam A, Wenham RM, Apte SM, Berglund AE, Lancaster JM (date unknown). BAD-mediated apoptotic pathway is associated with human cancer development. Vol. 35, 1081-7. Accepted, .
  • Apte SM, Bucana CD, Killion JJ, Gershenson DM, Fidler IJ (date unknown). Expression of platelet-derived growth factor and activated receptor in clinical specimens of epithelial ovarian cancer and ovarian carcinoma cell lines. Vol. 93, 78-86. Accepted, .
  • Liang MI, Aviki EM, Wright JD, Havrilesky LJ, Boyd LR, Moss HA, Jewell EL, Cohn DE, Apte SM, Timmins PF 3rd, Alvarez RD, Rathbun J, Lipinski E, White S, Siverio-Minardi D, Ko EM (date unknown). Society of gynecologic oncology future of physician payment reform task force: Lessons learned in developing and implementing surgical alternative payment models. Vol. 156, 701-709. Accepted, .
  • Abdallah R, Bush SH, Chon HS, Apte SM, Wenham RM, Shahzad MM (date unknown). Therapeutic Dilemma: Prognostic Factors and Outcome for Neuroendocrine Tumors of the Cervix. Vol. 26, 553-60. Accepted, .
  • Bush SH, Tollin S, Marchion DC, Xiong Y, Abbasi F, Ramirez IJ, Zgheib NB, Boac B, Judson PL, Chon HS, Wenham RM, Apte SM, Cubitt CL, Berglund AE, Havrilesky LJ, Lancaster JM (date unknown). Sensitivity of ovarian cancer cells to acetaminophen reveals biological pathways that affect patient survival. Vol. 4, 399-404. Accepted, .
  • Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Chan J, Cho KR, Cohn D, Crispens MA, DuPont N, Eifel PJ, Gaffney DK, Giuntoli RL 2nd, Han E, Huh WK, Lurain JR 3rd, Martin L, Morgan MA, Mutch D, Remmenga SW, Reynolds RK, Small W Jr, Teng N, Tillmanns T, Valea FA, McMillian NR, Hughes M, National Comprehensive Cancer Network. (date unknown). Cervical cancer. Vol. 11, 320-43. Accepted, .
  • Rishi A, Rollins M, Ahmed KA, Hunt DC, Sarkar P, Fernandez DC, Hoffman MS, Apte SM, Shahzad MMK, Chon HS, Chern JY, Wenham RM, Montejo ME (date unknown). High-dose intensity-modulated chemoradiotherapy in vulvar squamous cell carcinoma: Outcome and toxicity. Vol. 156, 349-356. Accepted, .
  • Bulls HW, Hoogland AI, Kennedy B, James BW, Arboleda BL, Apte S, Chon HS, Small BJ, Gonzalez BD, Jim HSL (date unknown). A longitudinal examination of associations between age and chemotherapy-induced peripheral neuropathy in patients with gynecologic cancer. Vol. 152, 310-315. Accepted, .
  • Boac BM, Xiong Y, Marchion DC, Abbasi F, Bush SH, Ramirez IJ, Khulpateea BR, Clair McClung E, Berry AL, Bou Zgheib N, Chon HS, Shahzad MM, Judson PL, Wenham RM, Apte SM, Berglund AE, Magliocco AM, Lancaster JM (date unknown). Micro-RNAs associated with the evolution of ovarian cancer cisplatin resistance. Vol. 140, 259-63. Accepted, .
  • Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Chan J, Cho KR, Cohn D, Crispens MA, Dupont N, Eifel PJ, Fader AN, Fisher CM, Gaffney DK, George S, Han E, Huh WK, Lurain JR 3rd, Martin L, Mutch D, Remmenga SW, Reynolds RK, Small W Jr, Teng N, Tillmanns T, Valea FA, McMillian N, Hughes M (date unknown). Uterine neoplasms, version 1.2014. Vol. 12, 248-80. Accepted, .
  • Bou Zgheib N, Marchion DC, Bush SH, Judson PL, Wenham RM, Apte SM, Lancaster JM, Gonzalez-Bosquet J (date unknown). Molecular determinants for lymph node metastasis in clinically early-stage endometrial cancer. Vol. 11, 323-329. Accepted, .
  • Mark J, Bush S, Glazer E, Strosberg J, Saglam O, Apte SM (date unknown). Metastatic VIPoma presenting as an ovarian mass. Vol. 17, 167-9. Accepted, .
  • Chen N, Chon HS, Xiong Y, Marchion DC, Judson PL, Hakam A, Gonzalez-Bosquet J, Permuth-Wey J, Wenham RM, Apte SM, Cheng JQ, Sellers TA, Lancaster JM (date unknown). Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel. Vol. 31, 376-83. Accepted, .
  • Chon HS, Marchion DC, Xiong Y, Chen N, Bicaku E, Stickles XB, Bou Zgheib N, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Lancaster JM (date unknown). The BCL2 antagonist of cell death pathway influences endometrial cancer cell sensitivity to cisplatin. Vol. 124, 119-24. Accepted, .
  • Bansal N, Marchion DC, Bicaku E, Xiong Y, Chen N, Stickles XB, Sawah EA, Wenham RM, Apte SM, Gonzalez-Bosquet J, Judson PL, Hakam A, Lancaster JM (date unknown). BCL2 antagonist of cell death kinases, phosphatases, and ovarian cancer sensitivity to cisplatin. Vol. 23, 35-42. Accepted, .
  • Ramirez I, Chon HS, Apte SM (date unknown). The role of surgery in the management of epithelial ovarian cancer. Vol. 18, 22-30. Accepted, .
  • Humphrey MM, Apte SM (date unknown). The use of minimally invasive surgery for endometrial cancer. Vol. 16, 30-7. Accepted, .
  • Hammer DA, Tempelman LA, Apte SM (date unknown). Statistics of cell adhesion under hydrodynamic flow: simulation and experiment. Vol. 19, 261-75; discussion 275-7. Accepted, .